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Chapter 1 has set out the scope, conceptual framework and structure of this 
book. This chapter and the next provide a detailed overview of how economic 
approaches are used for the evaluation of policy interventions in the areas of 
health promotion and disease prevention. Here, in Chapter 2, we provide an 
introduction to how economic analyses can be used as a tool to help inform 
decision- making processes on different potential investment choices for the 
promotion of better population health and well- being. Chapter 3 then goes on to 
look in detail at how outcomes and costs are assessed in economic evaluation. 
Both of these chapters are intended to provide readers with an understanding 
of the role of economic tools to help interpret the evidence reviewed in the rest 
of the book, and also to offer guidance to those who intend to contribute to the 
economic evidence base on health promotion and chronic disease prevention.
Chapter 1 highlighted the considerable challenges that policymakers face in 
promoting and protecting health around the globe. New estimates of the global 
burden of disease for noncommunicable diseases, including heart disease and 
stroke, diabetes, cancer, chronic lung diseases, low back pain and poor mental 
health, indicate that they account for more than 80 per cent of the burden of 
disease in Europe (Institute of Health Metrics 2013). Moreover, while average life 
expectancy at birth has been increasing, reaching 76.7 years in 2011, there are 
substantial disparities across countries. In 2011, life expectancy in the 15 countries 
that were European Union (EU) members before May 2004 was 81.3 versus 76.0 
in the 13 countries joining the EU since 2004, and just 69.8 for countries in the 
Commonwealth of Independent States (WHO Regional Office for Europe 2014).
The importance of addressing these challenges is recognized in the new 
health policy framework and strategy of the WHO European Region, Health 
2020 (WHO Regional Office for Europe 2013). This is focused on improving the 
health and well- being of populations, reducing health inequalities, strengthening 
public health and ensuring the sustainability of health systems. This builds on 
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an ever mounting body of literature emphasizing the importance of tackling 
the social determinants of health over which individuals may have little or 
no control (Commission on Social Determinants of Health 2008; Braveman et 
al. 2011). It takes a whole- of- government and whole- of- society perspective, 
emphasizing the importance of actions which go well beyond the traditional 
boundaries of the health sector and ministries of health.
Chapter 1 has also set out the economic rationale for investing in health 
promotion and disease prevention; a lack of intervention by government is 
likely to lead to a sub- optimal allocation of resources to these activities. It may 
also serve to widen inequalities in health. The challenge then is to determine 
just how to intervene, with the core question for policymakers in Europe and 
elsewhere being the extent to which investments in both upstream interventions 
that target the circumstances that produce adverse health behaviours, and 
downstream actions that aim to change adverse behaviours, represent a good 
use of the limited resources at our disposal.
From an economic perspective, how do different interventions stack up when 
compared with each other or against investment in the treatment of health 
problems? For example, are there potential gains to be made by reducing or 
delaying the need for the consumption of future health care resources? Are they 
more cost- effective for some population groups than others and, if so, will this 
widen inequalities in health? Might they limit some of the wider costs of poor 
health to society, such as absenteeism from work, poorer levels of educational 
attainment, higher rates of violence and crime and early retirement from the 
labour force due to sickness and disability?
To answer these questions, information is needed on both the effectiveness 
and cost- effectiveness of different actions in different contexts, taking into 
account some of the challenges associated with effective implementation. 
Economic analysis can help address many of these questions and as we shall 
go on to indicate it is now being increasingly used to look at the case for health 
promotion and disease prevention.
Resource scarcity and the role of economic analysis
If resources were limitless it would be relatively straightforward to argue 
for investment in disease prevention and health promotion actions of proven 
effectiveness. Resources are, however, scarce and careful choices have to be 
made. These decisions may be even more important in any downward phase in 
an economic cycle in countries, where public finances including health, social 
care and education budgets are under even greater pressure. Evidence on 
effectiveness alone is insufficient for decision- making; in addition to knowing 
what works and in what context, information on the economic impacts of these 
choices is required. Such economic evidence is increasingly a formal element 
of decision- making processes, and can be compelling in putting forward a case 
for policy change.
There are at least four key economic questions that can be helpful to decision- 
makers in the difficult task of allocating resources (Knapp and McDaid 2009) 
(see Box 2.1). In this chapter we will focus in particular on the third question, that 
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of classical economic evaluation – that is, establishing the cost- effectiveness of 
alternative policy options for health promotion and disease prevention. We now 
will briefly look at these four questions, then describe different approaches to 
economic evaluation, including how economic modelling tools can be used. We 
will then look at how the economic evidence base on health promotion and 
disease prevention has evolved.
The cost of not taking action
Economic methods can be used to assess the costs of not taking action. In 
the case of health promotion and disease prevention, this would include not 
only quantifying the resources needs and costs of delivering health and other 
services to treat what would have been preventable health problems, but also 
quantifying the broader impacts of risky behaviours and poor health. In the 
case of alcohol- related harm, for instance, this would include costs to the 
criminal justice system of alcohol- related crimes and the costs of alcohol- 
related road traffic accidents and workplace injuries (Anderson et al. 2013). 
At an even broader level this could also include estimating the costs of stigma 
and discrimination associated with some avoidable health problems such as 
HIV/AIDS (Brent 2013) or behavioural problems in children (Scott et al. 2001; 
Colman et al. 2009; McDaid et al. 2014).
Estimating the costs of intervention
A second question that economics can address is to determine the costs of 
intervention. This can include all the initial implementation costs associated with 
putting in place the necessary infrastructure for a health promotion programme, 
as well as the ongoing maintenance costs for that programme. This can go 
beyond costs to government or other programme funders; there may be further 
costs to society as a whole, for instance out- of- pocket costs that must be incurred 
Box­2.1 Economic questions to inform policymaking and practice
The costs of inaction: What are the economic consequences of not taking 
action to promote and protect the health of the population?
The costs of action: What would it cost to intervene by providing a 
promotion or preventive measure?
The cost- effectiveness of action: What is the balance between what it 
costs to intervene and what would be achieved in terms of better 
outcomes – e.g. emotional well- being, physical health, improved quality 
of life, educational performance?
The levers for change: What economic incentives can encourage more use 
of those interventions that are thought to be cost- effective and less use of 
those interventions which are not?
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by members of the population if they wish to make use of a health promotion 
programme or activity. One example of this, for instance, is the cost to families 
of purchasing bicycle helmets following the introduction of legislation on their 
mandatory use (Taylor and Scuffham 2002; Hendrie et al. 2004).
Informing the allocation of resources
Answering these first two questions provides valuable information to decision- 
makers, but it does not provide guidance on how best to allocate resources to 
promote and protect health. This is something that can be addressed by the third 
question which implies the use of economic evaluation techniques. Widely used 
in the health care, environmental and transport sectors, economic evaluation can 
be considered ‘the comparative analysis of alternative course of action in terms 
of both their costs and consequences’ (Drummond et al. 2005). It acknowledges 
that scarcity is an endemic feature of all societies and implies that investment in 
one specific public project will mean a lost opportunity to use these resources 
for another purpose. Even in the absence of long- term effectiveness data, as 
we shall discuss later, economic evaluation can use modelling techniques to 
assess the long- term costs and effects and/or identify the level of effectiveness 
a strategy would have to achieve to be considered cost- effective.
Economic evaluation techniques compare incremental changes in costs 
with incremental changes in outcomes for two or more policy options. If, 
using economic evaluation techniques, a new intervention is both less costly 
and more effective than the existing situation, then the decision is usually 
straightforward – invest in the new intervention. If it has poorer outcomes and 
costs more, it will also be rejected. But if an intervention is both more effective 
and more costly (or in theory less effective and less costly), then policymakers 
must make a value judgement as to whether it is worthwhile.
Care has to be taken in interpreting the results of economic evaluation. The 
resources and infrastructure available will influence that what may be deemed 
cost- effective in Ireland or France may not be in Tajikistan or Georgia. Something 
that is cost- effective when only looking at the impact to the health system may 
appear cost- ineffective when costs to the economy as a whole are considered. 
Furthermore, an intervention that does not appear cost- effective over a 12- month 
period may appear highly cost- effective if a longer time horizon is considered. 
Guidelines on the ways in which economic studies should be reported have been 
published (Husereau et al. 2013) and there are some databases, most notably, 
the NHS Economic Evaluation Database at the University of York, that provides 
independent critical appraisals of the quality of these studies.1
For all of these reasons the results of economic evaluations should not be 
used in isolation, and other factors will need to be taken into consideration 
as part of any decision- making process. Investment in the most cost- effective 
intervention might conflict with other policy goals, such as reducing inequality 
in health or non- health outcomes between social groups. Other economic inputs 
taken into deliberation may include the budgetary impact of implementing 
an intervention, the need to address any inequalities in outcomes between 
population sub- groups, issues of fairness in access to services and support, 
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and the economic impacts on the wider local economy of a population health 
measure, such as banning smoking in pubs and restaurants and local political 
concerns.
Using economic incentives to influence behaviour
The fourth question in Box 2.1 is concerned with how different economic 
incentives can be used as levers to encourage more use of those interventions 
that are demonstrated to be cost- effective, and less use of those interventions 
which are not. This might, for instance, involve looking at how the level of 
flexibility in the ways in which budgets are allocated influences the development 
of partnerships to deliver health promotion services across sectors (Johansson 
and Tillgren 2011; McDaid 2012). This is an issue that is discussed in detail 
in Chapter 14. It might also look at how different payment mechanisms and 
financial incentives in service contracts can influence the success of health 
promotion and disease prevention activities. The role of financial and other 
incentives to encourage a target population group to participate and/or sustain 
health promoting activities is another area of research that may be examined 
(Thomson et al. 2012). This fourth question also covers the long history of 
research looking at the links between taxation policy within one country or even 
across international boundaries and risky behaviours (Johansson et al. 2009; 
Doran et al. 2013; Johansson et al. 2014). In recent years, there has also been a 
growing interest in looking at how tools from behavioural science can be used to 
influence individual behaviours; one example of this is work looking at whether 
commitment contracts which financially reward individuals for achieving a 
health behaviour goal, such as losing weight or quitting smoking, really do lead 
to long- term sustained change (John et al. 2011; Relton et al. 2011; Allan et al. 
2012; Loewenstein et al. 2012; White et al. 2013).
Approaches to economic evaluation
Having briefly looked at each of the four questions in Box 2.1, we now focus 
on approaches to economic evaluation. A number of authors have looked at 
the strengths and weaknesses of different economic evaluation methods for 
health promotion and disease (Kelly et al. 2005; Cookson et al. 2009; McDaid and 
Needle 2009; Weatherly et al. 2009; Lorgelly et al. 2010; Marsh et al. 2012; McDaid 
and Suhrcke 2012). Chapter 3 discusses these issues in detail. Here we briefly 
introduce the main types of economic evaluation. They have much in common – 
for instance, they share a common approach to the conceptualization, definition 
and measurement of costs, but there are important differences in how they 
define and assess outcomes, primarily because they seek to answer slightly 
different questions.
If the question to be addressed by an economic evaluation is essentially 
about improving some specific aspect of health, information will be needed 
on the comparative costs of the different health promotion actions available 
(and also on the cost of a no- action option). The comparative outcomes may be 
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measured using some specific measure of health status. This would be known 
as cost- effectiveness analysis. While it is easy to understand it can be of limited 
use as the outcome measures used would vary from study to study, meaning 
that little could be said at a macro level about how best to use resources in a 
health promotion budget.
An alternative approach would be to measure all health- related outcomes 
using a common metric such as the quality- adjusted life- year (QALY) (see 
Chapter 3 for more on this). This approach is known as cost- utility analysis. 
Using a common metric, health system decision- makers can compare cost per 
QALY gained for very different health promotion and health care interventions. 
They can then take this information into account when making decisions on 
how to allocate their budgets.
However, throughout this volume many of the interventions that are 
described are likely to be delivered outside of the health system, for instance 
by ministries responsible for food standards, transport or education. In these 
cases, using even broader measures of impact that are relevant across all of 
these public policy areas can be helpful. The usual approach for such a broad 
impact measure is to value all outcomes in terms of money, leading to a form of 
evaluation called cost- benefit analysis.
These choices on economic evaluation technique do not have to be mutually 
exclusive: a single study can support more than one approach if the right 
combination of evaluative tools is used. However, guidelines from health 
technology assessment bodies tend to recommend the use of cost- utility analysis. 
In England, public health guidance developed by the National Institute for Health 
and Care Excellence (NICE) allows the use of cost- consequences analysis as an 
addendum to cost- utility analysis (Kelly et al. 2010). This approach can present 
cost per change in a range of natural health and non- health outcomes, such as 
heart attacks avoided or a reduction in crime rates. It is then up to policymakers 
to assess which outcome (if any) may be most important. Public health guidance 
from NICE also enables a broader perspective on costs than the conventional 
consideration of costs to the health and social care system seen in many health 
technology assessment systems elsewhere. It can, for instance, also examine 
the effects of workplace health promotion programmes on the costs to business 
of absenteeism and reduced productivity levels.
Cost- benefit analysis is widely used in the assessment of the economic 
case for health promoting actions in the fields of transportation and the 
environment, but is unusual in the health sector. The challenges of eliciting 
accurate monetary values for outcomes and negative public perceptions of 
valuing health in monetary terms, as illustrated in Chapter 3, may have limited 
the use and acceptability of cost- benefit analysis in the health sector (Rush 
et al. 2004; Kelly et al. 2005; McDaid and Needle 2009). 
How can economic modelling help?
Economic modelling techniques are widely used in making the case for health 
promotion and disease prevention interventions. There are many different 
reasons for making use of economic models (Box 2.2). Paramount is the need 
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to reduce any uncertainty about the strength of evidence on the effectiveness 
and costs of different interventions. Such uncertainty increases the likelihood 
of making a sub- optimal policy decision. One key cause of uncertainty is that 
many of the impacts of health promoting actions go well beyond the time frame 
covered by conventional evaluative studies. Modelling is often the only way 
of estimating the impacts of an intervention over the long term. For instance, 
many of the health- related benefits of avoiding the onset of obesity will not be 
manifest for several decades (Sassi 2010).
As subsequent chapters in this volume will show, economic models are very 
widely used to estimate benefits over many decades for disease prevention 
and health promotion (e.g. Wang et al. 2002; Wang et al. 2003; Chisholm et al. 
2004; Cobiac et al. 2009; Cecchini et al. 2010; Cobiac et al. 2010). Most trials or 
longitudinal studies only follow up participants for no more than a few years 
at best (Hodgson et al. 2007). Readers should also be aware that judging the 
success of investing in a health promotion programme based solely on the 
outcomes, say of a 12- month controlled study, may be misleading and very 
different from a study with the same programme evaluated over much a longer 
follow- up period (Haji Ali Afzali et al. 2012).
Models can extrapolate information from trials and literature to provide 
estimates of longer-term cost- effectiveness. They can make different 
assumptions, for instance on the persistence of effectiveness of any intervention, 
as well as the need for ongoing or booster sessions. These longer-term models 
can also be designed to take account of the risk of future negative events and 
patterns of disease progression. For instance, in the case of chronic mental 
disorders this may involve looking at the risk of a relapse or how past suicidal 
behaviour impacts on the risk of further suicidal events (McDaid 2014).
Models are also used to look at the impacts of adapting the evidence on 
effective interventions to different contexts and settings. Economic models 
are always prepared to inform deliberations at NICE, in England, on public 
health guidance (Kelly et al. 2010). These models often take effectiveness and 
resource use data reported in non- United Kingdom settings and adapt this to 
a United Kingdom context. Models might also be used to look at the minimum 
level of engagement and continued use of an intervention that would be needed 
for one to be considered cost- effective in everyday conditions.
Box­2.2 The role of economic modelling for health promotion and 
disease prevention
• Addressing uncertainty in the results of any one trial.
• Synthesizing data from multiple trials and effectiveness studies on 
different costs and effects of interventions, often using different head- 
to- head comparators rather than relying on findings from one study 
alone.
• Modelling the costs and effectiveness of different interventions for 
longer time periods than seen in most evaluative studies.
• Modelling potential intervention pathways, and their effectiveness 
and costs in contexts and settings where local empirical evidence is 
unavailable.
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• Modelling the costs and effectiveness of interventions for specific sub- 
population groups.
• Modelling the cost- effective implications of differing rates of coverage, 
uptake and continued engagement with different interventions.
A discussion of the strengths and weakness of different modelling approaches goes 
beyond the scope of this chapter, but this has been widely discussed in the literature 
(Barton et al. 2004; McDaid 2014), including in the context of health promoting 
interventions (Barton et al. 2011). Different modelling approaches involve different 
levels of complexity and time to develop. Some models can be constructed relatively 
quickly and do not require investment in expensive computing equipment. At the 
other end of the spectrum there are complex macro- simulation models that have 
been used to model some packages of preventive interventions, e.g. for obesity, 
diet and physical activities (Cecchini et al. 2010). These complex models, while in 
theory being more precise, can take a team of researchers many months to build. 
They can also require a large amount of computational power using mainframe 
computers – something which may not be available.
Growth in the use of economic evaluation to assess health  
promotion and disease prevention interventions
Many European countries have formally made use of economic evidence when 
considering whether to reimburse new health care interventions and procedures 
for some years (McDaid and Cookson 2003). Historically, less attention has 
focused on the strength of the evidence for most health promotion and disease 
prevention strategies. Although many complex health promotion and public 
health interventions do not lend themselves easily to evaluation through 
randomized controlled trials, the real challenge may not lie in scepticism over 
methodologies of evaluation, but rather in the very limited levels of resources 
available for evaluating many public health and health promoting interventions 
that do not have an obvious commercial appeal. This is particularly the case 
for those interventions focused on the social determinants of health that play a 
major role in influencing population health.
Without solid evidence on effectiveness it is nigh on impossible to determine 
the cost- effectiveness of any action. With little private sector motivation to 
invest in public health, research is largely reliant on funding from government 
and charitable foundations. Budgets for pubic health research are often modest, 
and until recently there appear to have been few incentives to undertake 
economic evaluations of public health and health promoting interventions (Hale 
2000; Godfrey 2001; Holland 2004; Kelly et al. 2005; McDaid and Needle 2009).
Therefore health technology assessment agencies and other comparable 
organizations have focused on the case for reimbursing what are often expensive 
new pharmaceuticals and technologies. Early assessments of the economic 
case for preventive actions focused on technologies that may have been more 
straightforward to evaluate, such as screening and vaccination policies, as well 
as assessing interventions to tackle already established poor health behaviours 
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such as smoking (McGhan and Smith 1996) and risky sexual practices (Wang 
et al. 2000). The impacts of changes in pricing policies and taxes on harmful 
behaviours have been examined for decades (Levy and Sheflin 1983; Ornstein 
and Levy 1983). Many interventions have also been evaluated within the context 
of decision- making processes in other sectors, as in the case of the economic 
appraisal of road safety interventions (Elvik et al. 2009).
In recent years there has been a growth in both the absolute number of 
economic evaluations that have been undertaken and the types of intervention 
that they cover (McDaid and Needle 2009; Weatherly et al. 2009; Saha et al. 
2010; Sassi 2010; Vos et al. 2010; McDaid and Suhrcke 2012; Owen et al. 2012; 
Alayli- Goebbels et al. 2013). Chapters 4 to 11 in this volume will go on to look 
at much of this evidence. There is increasingly a greater focus on complex 
interventions, including evaluations of combinations of interventions and some 
evaluation of behaviour change interventions. The increased availability of 
sophisticated modelling software has also allowed much more intricate analysis 
to be conducted, taking a very long- term or even lifetime perspective (Cecchini 
et al. 2010; Ortegon et al. 2012).
There has also been an increase in the use of economic evidence to inform 
formal decision- making processes at national and regional level, with actions 
identified in countries such as Australia, Belgium, Canada, Denmark, England, 
Finland, the Netherlands, New Zealand, Norway, Sweden and the US (McDaid 
and Suhrcke 2012). In Europe, NICE in England has been a pioneer on the use 
of economic evidence for decisions on health promotion and public health 
interventions delivered outside of the health system. It has been assessing the 
economic case for these interventions since 2005, publishing guidance which has 
been influenced by mandatory economic modelling work and systematic reviews 
of economic evidence (Owen et al. 2012). This guidance should be followed 
by health care system stakeholders and is discretionary for other relevant 
interested parties such as local government and private sector employers (Kelly 
et al. 2010).
Moving forward
The economic evidence base for health promotion and disease prevention 
continues to grow, and the importance of assessing the economic case for 
prevention is acknowledged in many health policy circles. Potentially, the 
economic benefits of investing in health promotion and disease prevention 
could be high, but it is important that well- designed evaluations are undertaken 
prior to large- scale investment. Adding an economic dimension retrospectively 
to those areas of public health where evidence on effectiveness is strong may 
be one pragmatic and relatively rapid way of helping to expand an evidence 
base which, as we shall see, is still dominated by studies from a handful of 
countries. Modelling techniques can also be used to help expand the evidence 
base and look at potential costs and benefits over different time periods, making 
different assumptions on effectiveness and resource configuration, in different 
geographical contexts and from the perspective of different budget holders or 
the economy as a whole.
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Many challenges lie ahead, including the ways in which outcomes will be 
measured. This is discussed fully in Chapter 3, but one issue for economic 
evaluation is to develop appropriate metrics to be able to compare improvements 
in health outcomes with improvements in well- being, where this is defined as 
being over and above the absence of illness. Well- being, for instance, has also 
been discussed in terms of the capability approach which suggests that well- being 
should be measured not according to what individuals actually do (functioning), 
but what they can do (capabilities) (Lorgelly et al. 2010). More can also be done 
to take on board equity, as well as efficiency concerns, when looking at health 
promotion and disease prevention; this challenge will be explored in Chapter 12. 
Another challenge will be to better translate economic evidence messages into 
implemented actions (Chapter 13), both within and beyond the health system. 
Chapter 14 will examine what more can be done to overcome barriers to more 
intersectoral working.
We have indicated in the first two chapters of this volume that there is 
much interest at a policy level on the potential for adopting health promotion 
and disease prevention strategies, but this interest does not always appear 
to be matched by investment. Recent analysis from the Organisation for 
Economic Co- operation and Development (OECD) found that more than 
three- quarters of OECD countries reported a cut in real- term spending on 
prevention programmes in 2011 compared to 2010, and half spent less than 
in 2008. There were cuts to spending on effective prevention programmes on 
obesity, harmful use of alcohol and smoking (OECD 2013). This is why it is vital 
to further strengthen the evidence base and communicate findings effectively. 
Cuts to health promotion and disease prevention budgets may reduce the 
pressure on health care finances in the short- term, but the longer-term impacts 
of poorer health are likely to have a much greater impact on future health care 
finances.
Note
1 http://www.crd.york.ac.uk/CRDWeb/
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